Stifel Financial Corp Purchases Shares of 117,461 Grifols, S.A. (NASDAQ:GRFS)

Stifel Financial Corp purchased a new stake in Grifols, S.A. (NASDAQ:GRFS - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm purchased 117,461 shares of the biotechnology company's stock, valued at approximately $1,043,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Quantinno Capital Management LP raised its stake in Grifols by 11.6% during the 3rd quarter. Quantinno Capital Management LP now owns 104,545 shares of the biotechnology company's stock worth $928,000 after buying an additional 10,830 shares during the period. Maven Securities LTD bought a new position in shares of Grifols during the 3rd quarter valued at about $250,000. Melqart Asset Management UK Ltd acquired a new position in shares of Grifols in the 3rd quarter valued at approximately $1,628,000. HighTower Advisors LLC increased its stake in Grifols by 12.5% during the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company's stock worth $123,000 after purchasing an additional 1,546 shares in the last quarter. Finally, Erste Asset Management GmbH bought a new stake in Grifols during the 3rd quarter worth approximately $242,000.

Analyst Ratings Changes

Separately, Berenberg Bank raised shares of Grifols to a "strong-buy" rating in a research note on Tuesday, October 29th.

Grifols Stock Up 1.8 %

NASDAQ GRFS traded up $0.14 on Tuesday, reaching $7.82. The company had a trading volume of 275,691 shares, compared to its average volume of 1,819,654. The company's fifty day moving average is $8.33 and its 200-day moving average is $8.12. Grifols, S.A. has a 1-year low of $5.30 and a 1-year high of $12.15. The firm has a market capitalization of $5.38 billion, a price-to-earnings ratio of 8.06 and a beta of 0.43. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.